Clinical Orthopaedics and Related Research ®

A Publication of The Association of Bone and Joint Surgeons ®

Tumor 241 articles

Articles

Osteoporosis in Children and Young Adults: A Late Effect After Chemotherapy for Bone Sarcoma

Ulrike Michaela Pirker-Frühauf MD, Jörg Friesenbichler MD, Ernst-Christian Urban MD, Barbara Obermayer-Pietsch MD, Andreas Leithner MD

Premature bone loss after childhood chemotherapy may be underestimated in patients with bone sarcoma. Methotrexate (MTX), a standard agent in osteosarcoma protocols, reportedly reduces bone mineral density (BMD). The literature, however, has reported cases of BMD reduction in patients with Ewing's sarcoma treated without MTX. Thus, it is unclear whether osteoporosis after chemotherapy relates to MTX or to other factors.

2011 Mid-America Orthopaedic Association Dallas B. Phemister Physician in Training Award: Can Musculoskeletal Tumors be Diagnosed with Ultrasound Fusion-Guided Biopsy?

Jad G. Khalil MD, Michael P. Mott MD, Theodore W. Parsons MD, Trevor R. Banka MD, Marnix Holsbeeck MD

Percutaneous biopsy for musculoskeletal tumors commonly relies on imaging adjuncts including ultrasound (US), CT, or MRI. These modalities however have disadvantages (US) or are cumbersome, not universally available, and costly (CT and MRI). US fusion is a novel technique that fuses previously obtained CT or MRI data with real-time US, which allows biopsies to be performed in an US suite. It has proven useful in various body systems but musculoskeletal applications remain scarce. Our goal is to evaluate the fusion technology and determine its ability to diagnose musculoskeletal tumors.

Prereferral MRI Use in Patients with Musculoskeletal Tumors Is Not Excessive

Christopher T. Martin MD, Jose Morcuende MD, PhD, Joseph A. Buckwalter MS, MD, Benjamin J. Miller MD

Inappropriate MRI use has been targeted as a particular area of concern in orthopaedics, but it is unclear whether and to what extent its use is inappropriate in musculoskeletal oncology.

A 16-year-old Boy with Multifocal, Painless Osseous Lesions

Ellen M. Dean MD, James C. Wittig MD, Camilo Vilalobos MD, Roberto A. Garcia MD

Femur Mass in a 43-Year-Old Woman

Yan Epelboym MPH, Kapil R. Desai MD, Roberto Garcia MD, James C. Wittig MD

Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma

Masanori Kawano MD, PhD, Ichiro Itonaga MD, PhD, Tatsuya Iwasaki MD, Hiroyuki Tsuchiya MD, PhD, Hiroshi Tsumura MD, PhD

We previously reported the combination of tumor cryotreatment with dendritic cells to promote antitumor immunity. The effect of the combination treatment with dendritic cells and antitransforming growth factor-β (anti-TGF-β) antibody on the elimination of regulatory T cells and the inhibition of tumor growth was investigated.

Simultaneous Anterior and Posterior Synovectomies for Treating Diffuse Pigmented Villonodular Synovitis

Wei-Ming Chen MD, Po-Kuei Wu MD, Chien-Lin Liu MD

The current treatment methods for diffuse intraarticular or extraarticular type pigmented villonodular synovitis (PVNS) include arthroscopic synovectomy or staged anterior and posterior open synovectomies. However, it is unclear whether simultaneous anterior and posterior synovectomies achieve local control and recovery of function.

Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group

Michael S. Isakoff MD, Donald A. Barkauskas PhD, David Ebb MD, Carol Morris MD, G. Douglas Letson MD

The pelvis is an infrequent site of osteosarcoma and treatment requires surgery plus systemic chemotherapy. Poor survival has been reported, but has not been confirmed previously by the Children’s Oncology Group (COG). In addition, survival of patients with pelvic osteosarcomas has not been compared directly with that of patients with nonpelvic disease treated on the same clinical trials.

Orthopaedic Case of the Month: Ossified Calf Mass in a 32-year-old Woman

Eniola T. Obadina MD, Donna G. Blankenbaker MD, Kirkland W. Davis MD, John P. Heiner MD